11.74
-0.76 (-6.08%)
News Mood
- MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
- MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing
AIStockmoo Score
| Value 30% | -0.5 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| Earns below its cost of capital. Returns on capital rising. info | |
| Timing 30% | -3.0 |
| From our AI technical analysis of the chart. info | NA |
| Downtrend over the past year. Far below its 52-week high. info | |
| Candle Patterns info | NA |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | 0.3 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly positive. info | |
| Smart Money 20% | 3.6 |
| Insider Activity info | NA |
| Institutions net +19.19% of shares in their latest 13F filings: 103 holders increased, 83 decreased (quarter to 30 Sep 2026). info | |
| Short interest -23.4% from 31 Aug to 30 Oct 2026, 2.9 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Price is low against its 52-week average. Up over 5 years. info | |
| Short-term momentum rising. info | |
| Price is between support and resistance. info | |
| Final Score | -0.24 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | MoonLake Immunotherapeutics | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| MLTX | - | - | - | 2.79 |
| TRML | 1 B | - | - | 4.76 |
| TECH | - | 0.44% | - | 5.28 |
| VKTX | - | - | - | 6.33 |
| VSTM | - | - | - | 76.50 |
| CRMD | - | - | - | 0.800 |
Select this tab to load the latest available analysis.
|
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 15.34% |
| % Held by Institutions | 96.70% |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 94.73%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 103 | 21,066,532 |
| Decreased | 83 | 10,045,773 |
| New | 38 | 8,512,207 |
| Sold out | 31 | 3,220,864 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 5,473,842 | 2.9 |
| 15 Oct 2026 | 7,833,997 | 4.1 |
| 30 Sep 2026 | 8,048,665 | 4.2 |
| 15 Sep 2026 | 8,947,906 | 6.1 |
| 31 Aug 2026 | 7,144,513 | 6.7 |
| 14 Aug 2026 | 6,819,147 | 4.2 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 12 Nov 2026 | Yahoo Finance |
MoonLake Immunotherapeutics (MLTX) Stock Could Be Above Fair Value On Book Value Concerns
MoonLake Immunotherapeutics has seen sharp swings over the past few years, and the latest share price level puts fresh focus on a simple question for you as an investor: Is the current valuation of MoonLake Immunotherapeutics stock meaningfully backed up by the strength of its balance sheet and its… |
| 11 Nov 2026 | Yahoo Finance |
MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing
MoonLake is developing Sonelokimab primarily for hidradenitis suppurativa (HS), a chronic inflammatory skin condition with limited effective treatments. |
| 10 Nov 2026 | Yahoo Finance |
Is MoonLake Immunotherapeutics (MLTX) Cheap On Earnings Losses And Sonelokimab Milestones?
MoonLake Immunotherapeutics (MLTX) just posted third quarter 2026 results, reporting a net loss of US$79.55 million and a diluted loss per share of US$0.93. The company also reaffirmed its focus on sonelokimab regulatory milestones. The latest earnings update landed after a sharp pullback, with… |
| 09 Nov 2026 | Yahoo Finance |
MoonLake Immunotherapeutics Stock In Focus After Quarterly Loss Update
MoonLake Immunotherapeutics reported third quarter 2026 results with a net loss of US$79.55 million and basic and diluted loss per share of US$0.93, and a nine month 2026 net loss of US$211.06 million with basic and diluted loss per share of US$2.74. The narrower quarterly loss per share compared… |
| 04 Nov 2026 | Yahoo Finance |
MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate-to-severe hidradenitis suppurativa, marking an important step towards potential U.S. approval and commercializationPositive Week 16 results from… |
| 25 Oct 2026 | Yahoo Finance |
MoonLake Immunotherapeutics (MLTX) Rides HS Narrative Following Rebound As Undervalued View Holds
Recent Performance Snapshot MoonLake Immunotherapeutics (MLTX) has drawn fresh attention after recent trading saw the share price close at $11.85. Performance has been mixed across timeframes and marked by sharp moves over the past 3 months. That recent jump in MoonLake Immunotherapeutics, with a… |
| 24 Oct 2026 | Yahoo Finance |
MoonLake Immunotherapeutics (MLTX) Stock Trades Above Fair Value On Balance Sheet Questions
MoonLake Immunotherapeutics has seen sharp swings in its share price in recent years, which puts fresh focus on what investors are really paying for on the balance sheet. With the stock last closing at US$11.85, the live question is how that market tag lines up with the company’s book value. The… |
| 22 Oct 2026 | Yahoo Finance |
AbbVie Slips Behind Rivals as Lutikizumab Hits 31.4% Response in HS Trial
Key TakeawaysAbbVie’s lutikizumab met its Phase 3 goal in hidradenitis suppurativa, with 31. 4% of patients reaching HiSCR75 at Week 16 versus 23… |
| 22 Oct 2026 | Yahoo Finance |
MoonLake Soars 18% as Rival AbbVie’s Skin Disease Trial Data “Underwhelms”
Key TakeawaysMoonLake shares jumped 18% today after AbbVie reported Phase 3 results for a rival hidradenitis suppurativa drug. AbbVie’s lutikizumab beat placebo by 8 percentage points on its main goal, a result RBC Capital called underwhelming. |
| 16 Oct 2026 | Yahoo Finance |
MoonLake Immunotherapeutics Makes Case for Sonelokimab Approval, RBC Says
MoonLake Immunotherapeutics (MLTX) made a "reasonably solid" case for the approvability of sonelokim… |
| 05 Oct 2026 | Yahoo Finance |
MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says
MoonLake Immunotherapeutics (MLTX) could receive US Food and Drug Administration approval for sonelo… |
| 21 Sep 2026 | Yahoo Finance |
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics)… |
| 11 Sep 2026 | Yahoo Finance |
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high. |
| Show more | ||
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |